|
GB202003057D0
|
|
Medicament and use thereof
|
|
GB201902087D0
|
|
Medicament and the use thereof
|
|
GB201802743D0
|
|
Medicament and use thereof
|
|
GB201501800D0
|
|
Treatment of medical conditions
|
|
GB201408171D0
|
|
Formulation and method of manufacture
|
|
GB201322948D0
|
|
Improved formulation
|
|
GB201309760D0
|
|
Assay
|
|
US2013344102A1
|
|
Formulation
|
|
AU2013282995A1
|
|
Formulation comprising CRH and alpha - 2 - immunoglobulin
|
|
NZ723827A
|
|
A method of manufacturing a stabilised complex of corticotropin releasing hormone (crh) and alpha-2 macroglobulin
|
|
GB201114710D0
|
|
Treatment of hepatitis c
|
|
GB201014736D0
|
|
Treatment of hepatitis C
|
|
GB0915434D0
|
|
Treatment of hepatitis C
|
|
GB0910032D0
|
|
Use of serum composition to reduce the levels of TNF and/or VEGF in mammals
|
|
GB0904073D0
|
|
Treatment of influenza
|
|
GB0816217D0
|
|
Treatment of hepatitis C
|
|
GB0804468D0
|
|
Treatment of influenza
|
|
GB0717139D0
|
|
Treatment of hepatitis C
|
|
GB0704989D0
|
|
Treatment of influenza
|
|
GB0617310D0
|
|
Treatment of hepatitis c
|
